These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 635985)

  • 1. Ia versus K/D antigens in immunological enhancement of tumor allografts.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1978 Apr; 25(4):182-7. PubMed ID: 635985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ia versus K/D antigens in immunological enhancement of tumour allografts. II. Studies with alloimmune sera prepared in recombinant strains.
    Duc HT; Kinsky RG; Voisin GA
    Ann Immunol (Paris); 1979; 130C(3):461-74. PubMed ID: 475347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dominant role of Ia antibodies in the passive enhancement of H-2 incompatible skin grafts.
    Staines NA; Guy K; Davies DA
    Eur J Immunol; 1975 Nov; 5(11):782-9. PubMed ID: 802473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of alloantibodies and suppressor cells in allografted mice treated for passive enhancement.
    Duc HT; Kinsky RG; Monnot P; Voisin GA
    Cell Immunol; 1985 Oct; 95(1):180-94. PubMed ID: 4028170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deviation of humoral and cellular alloimmune reactions by placental extracts.
    Duc HT; Massé A; Bobé P; Kinsky RG; Voisin GA
    J Reprod Immunol; 1985 Jan; 7(1):27-39. PubMed ID: 3973852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antigenic sites implicated in tumour allograft enhancement].
    Duc HT; Kinsky RG; Voisin GA
    Ann Immunol (Paris); 1977; 128(1-2):19-20. PubMed ID: 322579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of T and B lymphocytes in vitro. III. Presence of Ia determinants on allogeneic effect factor.
    Armerding D; Sachs DH; Katz DH
    J Exp Med; 1974 Dec; 140(6):1717-22. PubMed ID: 4139236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin graft enhancement studies with antigenic differences arising from the H-2K, H-2D, and H-2L loci.
    McKenzie IF; Henning MM; Morgan GM
    Transplantation; 1980 Jun; 29(6):439-43. PubMed ID: 6996234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of immune responsiveness to tumour grafts (enhancement or inhibition) induced in mice by allogeneic embryos.
    Vlachov K; Kinsky RG; Voisin GA
    Folia Biol (Praha); 1983; 29(6):419-23. PubMed ID: 6667745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of graft-versus-host reaction on the immune response to alloantigens and growth of a syngeneic tumor.
    Zaleski M
    Exp Hematol; 1975 Jan; 3(1):12-21. PubMed ID: 238866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
    Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mononuclear phagocytes: a major population of effector cells responsible for rejection of allografted tumor cells in mice.
    Yoshida R; Takikawa O; Oku T; Habara-Ohkubo A
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1526-30. PubMed ID: 1996352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
    Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
    J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive allograft enhancement by subclasses of polyclonal antibodies directed toward restricted regions of the major histocompatibility complex.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1982 May; 33(5):492-9. PubMed ID: 6806954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential destructive and enhancing effects of anti-H-2K, H-2D, and anti-Ia antisera on murine skin allografts.
    McKenzie IF; Henning MM
    J Exp Med; 1978 Feb; 147(2):611-6. PubMed ID: 342669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of hyperacute rejection of skin allografts by CD8+ lymphocytes.
    Yoshimura R; Chargui J; Aitouche A; Veyron P; Touraine JL
    Transplantation; 2000 Apr; 69(7):1452-7. PubMed ID: 10798770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of anti-H-2K and H-2D alloantibodies in enhancement and acute antibody-mediated rejection of mouse skin allografts.
    de Waal RM; Capel PJ; Koene RA
    J Immunol; 1980 Feb; 124(2):719-23. PubMed ID: 6985936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.
    Germain RN; Dorf ME; Benacerraf B
    J Exp Med; 1975 Oct; 142(4):1023-8. PubMed ID: 809532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.